Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

Phase 2 Recruiting 75 enrolled The University of Texas Health Science Center, Houston National Institute on Drug Abuse (NIDA) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD). This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/).

Timeline

Start: 2026-01-15
Primary completion: 2029-01-28
Completion: 2029-02-28

Publications

Yammine L, Versace F, Green CE, Webber HE, Yoon JH, Gutierrez AD, Leonard SJ, Weaver MF, Schmitz J. Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. BMJ Open. 2026 May 20;16(5):e115675. doi: 10.1136/bmjopen-2025-115675.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	1 mg	Subcutaneous

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

Summary

Timeline

Publications

Drugs

Indications